Assembly Biosciences Presents Positive Interim Data from Phase 1a and 1b Studies of ABI-H0731 in HBV Patients in a Late-Breaker Session at the EASL Conference

    NEXT STORY
    Helsinn Provides Grant for ESMO’s Preceptorship Programme for Supportive and Palliative Care
    PREV STORY
    GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    RECORDATI ACQUIRES THE SWISS PHARMACEUTICAL COMPANY PRO FARMA

    MILAN, Italy, July 14, 2016 (GLOBE NEWSWIRE) -- Recordati announces the acquisition of 100% ...

    author_avatar
    NASDAQ Market News

    Bavarian Nordic Announces Collaboration to Evaluate CV301 and Tecentriq in Bladder Cancer

    Collaboration is the second to evaluate a combination of CV301 with a checkpoint inhibitor ...

    author_avatar
    NASDAQ Market News

    Psoria-Shield, Inc. Expands Relationship with Prominent Healthcare Organization

    HOFFMAN ESTATES, IL, June 19, 2018 (GLOBE NEWSWIRE) -- Wellness Center USA, Inc. (OTCQB: WCUI), ...

    author_avatar
    NASDAQ Market News